Boyd, Zachary
Bristol-Myers Squibb (United States)
2 papers on CoChat
Most cited papers
- Verified
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 2,199
- Verified
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology
Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis
Cited by 407
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free